Figure 3From: Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial Responders: ≥30% Improvement from Baseline in PANSS Total Scores. The responder rates were significantly higher with paliperidone palmitate (all dose groups) than with placebo by the Day 36 timepoint.Back to article page